SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalBurzynski Research Institute (BZYR)


Previous 10 Next 10 
To: Timothy Gau who wrote (1)2/23/1997 4:01:00 PM
From: DrGamble
   of 15
 
Here is the full story from Houston Chronicle, the trial had been
going on for several weeks now (I believe). The jury should have
a verdict by sometime next week. This stock was sleeping around
.10 for a long time but have jumped up to 1.00 in the past week.
IMHO, If the jury render the not-guilty verdict then this stock will
have some life otherwise it will go back to "sleeping beauty" at .10
again.

BTW, I bought 5,000 shares at .10 several years ago.

-----------

8:12 PM 11/20/1995

Doctor indicted on fraud charges related to cancer drug

By DEBORAH TEDFORD
Copyright 1995 Houston Chronicle

A Houston doctor who developed a controversial cancer drug and was investigated for 12 years was indicted Monday on 75 charges of mail fraud, contempt and violations of U.S. Food and Drug Administration laws.

The protracted investigation of Stanislaw Burzynski and The Burzynski Research Institute had caused U.S. Rep. Joe Barton, R-Ennis, to say it smacked of a vendetta.

In September, Barton and his subcommittee on oversight and investigations began investigating charges the U.S. attorney's office here and the FDA have participated in a campaign of harassment against Burzynski since 1983.

However, U.S. Attorney Gaynelle Griffin Jones said Monday afternoon the investigation was so lengthy because the FDA has been attempting to work with Burzynski for years.

The charges stem from a cancer drug Burzynski developed -- antineoplaston -- that initially was made from human urine and is now made from a synthesized version.

The drug is manufactured in Stafford and dispensed through Burzynski's clinic at 12000 Richmond in Houston.

Prosecutors allege he used the non-FDA-approved drug on more than 2,500 patients for a variety of illnesses -- AIDS, arthritis, cancer, lupus, multiple sclerosis and Parkinson's disease. Forty of the counts charge Burzynski with introducing an unapproved new drug into interstate commerce.

Jones said her office's pursuit of the case demonstrates her commitment to investigating health care fraud and other health care-related offenses.

But Richard Jaffe, attorney for Burzynski, said there has been no fraud, that the Polish-born doctor has received FDA approval on Investigational New Drug (IND) applications for every drug he uses.

He also said Burzynski, 53, has FDA permission to ship the drug abroad in some cases, and also ships it in interstate commerce under compassionate use" INDs --again with FDA approval.

Elaine Crosby, director of compliance for the FDA, was present when Jones announced the indictments. Although Crosby read a brief statement reiterating the FDA's goal of protecting the public health, Jones blocked media attempts to ascertain exactly what approvals the FDA had given Burzynski.

Burzynski and the institute also are charged with 34 counts of mail fraud for allegedly submitting false claims for payment to health insurance providers.

In 1983, the FDA sought an injunction to keep Burzynski from treating advanced cancer patients with his antineoplaston drug. Then-U.S. District Judge Gabrielle McDonald denied the request, but forbade Burzynski from shipping the drug across state lines because it had not gone through the FDA approval process.

The doctor and the clinic are charged with being in contempt of McDonald's order because they allegedly delivered the drug into interstate commerce without following the FDA's regulations for experimental drugs.

The indictment further charges that delivery of the drug within Texas also was prohibited by state law.

In 1988, the Texas Department of Health said Burzynski's use of the unproven drug violated the Food, Drug and Cosmetic Act, and the state attorney general's office sued him in 1992.

That suit is on hold pending the outcome of a like case involving the Texas Board of Medical Examiners.

In that case, the board -- contrary to a finding by an administrative law judge -- said in 1994 it was illegal for Burzynski to treat patients in Texas, and placed his license on probation for 10 years.

A state district judge in Austin overturned the board's action and dismissed the case. It is currently under appeal.

Jones said Burzynski and the institute grossed more than $40 million from 1988 through 1994 from producing, prescribing and selling the non-approved drug.

The case was investigated by the FDA and the Postal Inspection Service.

Share RecommendKeepReplyMark as Last Read


To: Timothy Gau who wrote (1)2/23/1997 10:19:00 PM
From: DrGamble
   of 15
 
Tim,
For more fact about this legal battle, see this article :
cancermed.com

Share RecommendKeepReplyMark as Last Read


To: DrGamble who wrote (3)2/25/1997 12:50:00 AM
From: Carson O. Ray, Jr.
   of 15
 
Just noticed this thread. I collected a good deal of info. on Dr. B. some mo's ago while gathering info. for a cousin-in-law diagnosed w/ brain cancer. At this late hour I don't have to try to find it (& I didn't save the URL's anyway), but he has his own web site w/ lots of data; & there are some other links from cancer sites w/ info. Also, get to the Houston Chronicle online site, and search their database for stories about him.

There's much to point to the possibility that he's eccentric, stubborn, very suspicious of gov't interference (orig. due to his early experiences w/ Polish/communist beurocracies)... but is truly on to something. Several patients have been tracked down & interviewed after long-term remissions. Others have died, but he doesn't begin to guarantee that tough cases have a high chance of success. He could be onto a true hi-rate cure; he could be a charlatan; or he could sincerely think he has a cure but doesn't for all "we" know.

Investment-wise it's truly a crap-shoot. How's this for a strategy (ignoring comm's): If it drops to 0.15, buy 20K shares ($3,000). Sell 10K at 0.30 to recoup investment. Sell 5K more if it gets to 0.50 for a nice $2.5K profit, & the rest if it hits $1 for $5K more? Risk vs. reward may not be bad....

Share RecommendKeepReplyMark as Last Read


To: Carson O. Ray, Jr. who wrote (4)3/3/1997 1:24:00 PM
From: DrGamble
   of 15
 
The verdict is "NOT GUILTY". That is the latest news ...

Share RecommendKeepReplyMark as Last Read


To: DrGamble who wrote (5)3/3/1997 3:27:00 PM
From: Carson O. Ray, Jr.
   of 15
 
NO -- "mis-trial" is the verdict. After 7 days deliberation w/ no verdict, judge declared mis-trial, & acquitted him on 34 of the 75 charges... he can still be re-tried on the other 41 charges of contempt & violations of USFDA rules. Go to Houston Chronicle home page (below). I think you can read it "free" today; if you have to search, you must register (also free):

chron.com

Minutes ago ask was about 56 cents; bid a DOLLAR! (some spread!!) Up 12+ %

Share RecommendKeepReplyMark as Last Read


To: Carson O. Ray, Jr. who wrote (6)3/7/1997 1:59:00 AM
From: DrGamble
   of 15
 
Did you watch the segment about Dr. Brezynski on CBS 48hrs tonight?

Share RecommendKeepReplyMark as Last Read


To: DrGamble who wrote (7)3/11/1997 5:06:00 PM
From: Carson O. Ray, Jr.
   of 15
 
(Late answer) No -- Left Thur. eve. for Fla. Just got back Mon. PM.
What did Dan Rather (who started his career w/ CBS in Houston) have to say? One of those news shows did a fairly detailed story on Dr. B. a few years ago.

Share RecommendKeepReplyMark as Last Read


To: DrGamble who wrote (2)12/10/1997 10:17:00 PM
From: mike head
   of 15
 
Hi, Michelle. Is anybody still following this thread? Interesting press release today-- results of PII trials and a proposed NDA in early '98. I'll post it if there's anyone here. Pax et Bonum, mch

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: mike head who wrote (9)12/14/1997 8:01:00 PM
From: paul j. gourley
   of 15
 
Mike, I"m very happy to see a current posting. I would very much like to see any current info on this stock. I'm long on this one, I really think something will come of it by the end of next year(In my own opinion) Thanks for any info you can provide.

Paul

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: paul j. gourley who wrote (10)12/14/1997 11:03:00 PM
From: mike head
   of 15
 
OK, Paul, here it is (I hope)
ÿ

ÿ Tell Me More - From Infoseek

Burzynski Research Institute Advances Clinical Trials for New Cancer Treatment and Completes New SEC Filing

December 10, 1997 11:26 AM EST



HOUSTON--(BUSINESS WIRE)--Dec. 10, 1997--Burzynski Research Institute Inc. (OTC Bulletin Board: BZYR) has filed a Form 10SB with the Securities and Exchange Commission which will make it a reporting company and allow the Company's stock to be marketed and supported by NASD broker/dealers.

Additionally, the Company announced a new clinical trial earlier this year for its experimental drugs, ANTINEOPLASTONS, for the treatment of liver cancer. Currently, Burzynski Research Institute is sponsoring a total of 72 Phase II Clinical Trials of ANTINEOPLASTONS in the treatment of a variety of cancer types and advanced stages. Early clinical results indicate particular promise with malignant brain tumors and lymphomas.

An interim analysis of three clinical studies indicates that from 33% to 50% of evaluable brain tumor patients accomplished either complete tumor elimination or reduction of tumor size by more than 50%.

ANTINEOPLASTONS are peptides, amino acid derivatives and certain organic acids that occur naturally in healthy individuals and, according to CEO and founder, Stanislaw R. Burzynski, M.D., Ph.D., may constitute the body's first and most effective line of defense against cancer.

The Company plans to submit the results of its current clinical trials to the FDA in January, 1998. If FDA finds the results of the trials sufficiently promising, Burzynski Research Institute Inc. will initiate a procedure to generate data which will support a New Drug Application (NDA).

Burzynski Research Institute stock is publicly traded on the OTC. Earlier this year, BRI retained the services of Brewer-Gruenert Capital Advisors, L.L.C., in Houston, to guide the Company in preparing for expected growth based upon its expectations of the positive results of the latest round of clinical trials.

c Business Wire. All rights reserved.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10